Updated March 19, 2013, at 11:30 a.m. to reflect that the quote in paragraph 6 came from an ACC press release, not an Edwards press release.
Replacement Heart Valves
Early results “encouraging” for Edwards’ redesigned Sapien XT valve
FDA considers patent extension for Edwards’ Sapien TAVI heart implant
Medtronic pays $84M in damages for Edwards TAVI patent infringement
UPDATE: FDA warns doc on CoreValve heart implant trial record-keeping issues
TAVI: Medtronic lands European win for next-gen Engager heart valve
Medical device giant Medtronic (NYSE:MDT) won European regulatory approval for its Engager transcatheter aortic valve implantation system, the company announced today.
The CE Mark indication includes approval for transapical delivery of the valve in treatment of patients with aortic stenosis who are too sick to undergo traditional surgery.
Medtronic wins FDA nod for pulmonary valve trial
Medtronic (NYSE:MDT) said the FDA approved an early trial of its native outflow tract transcatheter pulmonary valve under a new agency program for early feasibility studies.
The TPV device is designed for patients born without a right ventricle-to-pulmonary artery conduit, which provides blood to the lungs, as an alternative to open heart surgery.
Direct Flow aims to use heart valve giants’ experience against them
Being one of the smallest players on the field means you’ve got to differentiate yourself to stand out against the titans of the game, and that’s what Direct Flow Medical CEO Bernie Lyons aims to do.
Researchers find a genetic marker for aortic valve disease
A team of researchers have pinpointed a gene that may be responsible for double a patient’s risk of calcium buildup in the aortic valve, a condition linked with heart failure, stroke and sudden cardiac death.
The finding may lead to new research and therapies, which are very limited for patients with narrowing, or stenosis, of the aortic valve.
Edwards Lifesciences posts Q4, 2012 gains, confirms guidance
Edwards Lifesciences (NYSE:EW) handily beat Wall Street’s expectations for its 4th-quarter and 2012 profits and confirmed its outlook for 2013 today after the market’s close.
St. Jude expands European TAVI trial to include larger valves
St. Jude Medical (NYSE:STJ) researchers implanted the 1st patient with a larger-sized Portico transcatheter aortic valve as part of the medical device maker’s ongoing Portico TF EU trial.